FY2026 EPS Estimates for Pharming Group Cut by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – HC Wainwright dropped their FY2026 earnings per share estimates for shares of Pharming Group in a note issued to investors on Monday, September 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $0.43 per share for the year, down from their prior estimate of $0.50. HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.25 per share.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.

A number of other equities analysts have also commented on PHAR. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Canaccord Genuity Group raised their target price on Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Finally, Zacks Research cut Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, Pharming Group currently has a consensus rating of “Hold” and an average price target of $38.67.

Pharming Group Stock Down 3.5%

PHAR opened at $10.82 on Tuesday. Pharming Group has a 12 month low of $9.62 and a 12 month high of $21.34. The company has a market cap of $765.82 million, a PE ratio of 90.17 and a beta of 0.01. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. The company has a 50 day moving average of $12.00 and a 200 day moving average of $13.80.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.